EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieLeitlinie

Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial

Alexander J Blood iD, Lee-Shing Chang, Shahzad Hassan iD, Jacqueline Chasse, Gretchen Stern iD, Daniel Gabovitch iD, David Zelle iD, Caitlin Colling, Samuel J Aronson iD, Christian Figueroa, Emma Collins, Ryan Ruggiero und 8 weitere

Circulation · 04.06.2024 · 149 (23) · 1802-1811

DOI: 10.1161/circulationaha.124.069494 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 04.06.2024. Verfasst von Alexander J Blood und 19 weiteren Autor:innen. Beteiligte Einrichtung: Accelerator for Clinical Transformation (A.J.B., S.H., J.C., G.S., D.G., D.Z., S.J.A., C.F., E.C., R.R., J.P., T.A.G., C.P.C., B.M.S.), Brigham and W…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Novo Nordisk, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Several SGLT2i (sodium-glucose transport protein 2 inhibitors) and GLP1-RA (glucagon-like peptide-1 receptor agonists) reduce cardiovascular events and improve kidney outcomes in patients with type 2 diabetes; however, utilization remains low despite guideline recommendations. METHODS: A randomized, remote implementation trial in the Mass General Brigham network enrolled patients with type 2 diabetes with increased cardiovascular or kidney risk. Patients eligible for, but not prescribed, SGLT2i or GLP1-RA were randomly assigned to simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP1-RA (ie, Simultaneous) or 2 months of virtual education followed by medication prescription (ie, Education-First) delivered by a multidisciplinary team driven by nonlicensed navigators and clinical pharmacists who prescribed SGLT2i or GLP1-RA using a standardized treatment algorithm. The primary outcome was the proportion of patients with prescriptions for either SGLT2i or GLP1-RA by 6 months. RESULTS: Between March 2021 and December 2022, 200 patients were randomized. The mean age was 66.5 years; 36.5% were female, and 22.0% were non-White. Overall, 30.0% had cardiovascular disease, 5.0% had cerebrovascular disease, and 1.5% had both. Mean estimated glomerular filtration rate was 77.9 mL/(min‧1.73 m 2 ), and mean urine/albumin creatinine ratio was 88.6 mg/g. After 2 months, 69 of 200 (34.5%) patients received a new prescription for either SGLT2i or GLP1-RA: 53.4% of patients in the Simultaneous arm and 8.3% of patients in the Education-First arm ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansFemaleMaleAgedMiddle AgedPatient Education as TopicHypoglycemic AgentsPractice Guidelines as TopicCardiovascular DiseasesTelemedicineGuideline AdherenceTreatment OutcomeGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

cardiovascular diseasesdiabetes mellitus, type 2drug therapyglucagon-like peptide receptorssodium-glucose transport proteinstelemedicine

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Accelerator for Clinical Transformation (A.J.B., S.H., J.C., G.S., D.G., D.Z., S.J.A., C.F., E.C., R.R., J.P., T.A.G., C.P.C., B.M.S.), Brigham and Women's Hospital, Boston, MA.
  • Divisions of Cardiovascular Medicine (A.J.B., S.H., J.C., J.P., T.A.G., C.P.C., B.M.S.), Brigham and Women's Hospital, Boston, MA.
  • Harvard Medical School, Boston, MA (A.J.B., L-S.C., C.C., J.P., T.A.G., C.P.C., D.J.W., B.M.S.).
  • Endocrinology, Diabetes, and Hypertension (L-S.C.), Brigham and Women's Hospital, Boston, MA.
  • Personalized Medicine, Mass General Brigham, Cambridge (S.J.A.).
  • Novo Nordisk, Inc., Plainsboro, NJ (E.Z., J.N., C.R.).

ORCID-Profile: Alexander J Blood, Shahzad Hassan, Gretchen Stern, Daniel Gabovitch, David Zelle, Samuel J Aronson, Emily Zacherle, Carey Robar, Jorge Plutzky, Thomas A Gaziano, Christopher P Cannon, Deborah J Wexler

Förderung

  • Novo Nordisk, Inc

Zitieren

APA

Blood, A. J., Chang, L. S., Hassan, S., Chasse, J., Stern, G., Gabovitch, D., Zelle, D., Colling, C., Aronson, S. J., Figueroa, C., Collins, E., Ruggiero, R., Zacherle, E., Noone, J., Robar, C., Plutzky, J., Gaziano, T. A., Cannon, C. P., Wexler, D. J., & Scirica, B. M. (2024). Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial. Circulation, 149(23), 1802-1811. https://doi.org/10.1161/circulationaha.124.069494

Vancouver

Blood AJ, Chang LS, Hassan S, Chasse J, Stern G, Gabovitch D, et al. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial. Circulation. 2024;149(23):1802-1811. doi:10.1161/circulationaha.124.069494

BibTeX
@article{Blood2024,
  author = {Blood, Alexander J and Chang, Lee-Shing and Hassan, Shahzad and Chasse, Jacqueline and Stern, Gretchen and Gabovitch, Daniel and Zelle, David and Colling, Caitlin and Aronson, Samuel J and Figueroa, Christian and Collins, Emma and Ruggiero, Ryan and Zacherle, Emily and Noone, Joshua and Robar, Carey and Plutzky, Jorge and Gaziano, Thomas A and Cannon, Christopher P and Wexler, Deborah J and Scirica, Benjamin M},
  title = {Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {23},
  pages = {1802--1811},
  doi = {10.1161/circulationaha.124.069494}
}
Kostenlos starten →